급성허혈성 뇌졸중 진단과 치료 시장 : 유형별, 최종사용자별 - 세계 기회 분석과 산업 예측(2023-2032년)

Acute Ischemic Stroke Diagnosis and Treatment Market By Type, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 8,215,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,763,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

급성허혈성 뇌졸중(AIS) 진단과 치료 시장은 2022년에 51억 달러로 평가되며, 2023-2032년 CAGR 6.1%로 성장하며, 2032년에는 92억 달러에 달할 것으로 예측됩니다.

급성허혈성 뇌졸중 진단과 치료 시장은 헬스케어 부문으로부터의 진단 기술에 대한 수요의 증가에 의해 2023-2032년 6.1%의 대폭적인 성장률을 기록할 가능성이 높습니다.

급성 허혈성 뇌졸중(AIS)은 사망 원인 중 4위이며 성인 장애의 주요 원인입니다. AIS를 치료하는 약리학적 접근법은 주로 재조합 조직 플라스미노겐 활성화 인자(tPA)라고도 알려진 알테플라제를 이용한 정맥내 혈전 용해 요법을 중심으로 이루어집니다. 중심으로 도입됩니다. 알테플라제의 정맥 투여는 플라스미노겐의 가수분해를 촉매하여 단백질 분해 효소인 플라스민을 형성하여 혈전 용해를 촉진합니다.

급성 허혈성 뇌졸중 진단 및 치료 시장은 허혈성 뇌졸중 유병률 증가로 인해 크게 성장하고 있습니다. 예를 들어 World Stroke Organization Global Stroke Fact Sheet 2022에 따르면 매년 760만 건 이상의 허혈성 뇌졸중이 새롭게 발생하고 있으며, 전 세계에서 전체 뇌졸중의 62% 이상이 허혈성 뇌졸중입니다.

그러나 허혈성 뇌졸중 진단 및 치료 비용이 높기 때문에 시장 성장은 제한적입니다. 예를 들어 세계뇌졸중기구(WSO)에 따르면 Lancet Public Health 논문에 따르면 뇌졸중의 치료, 재활 및 간접비용은 연간 7,000억 달러 이상으로 추정됩니다. 이처럼 높은 진단 및 치료 비용은 시장 성장에 부정적인 영향을 미칩니다.

한편, 다음과 같은 혈전 용해제를 포함한 치료 옵션이 계속 발전하고 있습니다.

• 알테플라제 및 혈전제거술과 같은 혁신적인 기계적 중재를 포함한 치료 옵션의 지속적인 발전은 급성 허혈성 뇌졸중 시장의 성장을 가속하고 있습니다. 이러한 발전은 급성 허혈성 뇌졸중의 효과적이고 시기적절한 관리에 기여하고 있습니다.

급성 허혈성 뇌졸중 진단 및 치료 시장은 유형, 최종사용자, 지역으로 분류됩니다. 유형별로 시장은 진단과 치료로 분류됩니다. 진단 분야는 컴퓨터 단층 촬영, 자기공명영상, 경동맥 초음파, 뇌혈관조영술, 심전도, 심초음파, 기타로 세분화됩니다. 치료 부문은 혈전 용해 요법과 기계적 혈전 제거술로 나뉩니다. 혈전 용해 요법은 다시 조직 플라스미노겐 활성화제, 항혈소판제, 기타 활동으로 나뉩니다. 기계적 혈전제거술 부문은 스텐트 리트리버와 흡입 카테터, 그리고 조합(스텐트 리트리버와 흡입 카테터)으로 분류됩니다. 최종사용자에 따라 병원 및 클리닉, 진단 실험실 및 영상 진단센터, 기타로 분류됩니다.

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장의 정의와 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 촉진요인
    • 뇌졸중 발증률의 증가
    • 영상 기술의 진보
    • 치료 옵션의 혁신
  • 억제요인
    • 혁신적 치료법의 고비용
  • 기회
    • 신흥 시장에서 높은 시장 성장의 가능성

제4장 급성 허혈성 뇌졸중 진단과 치료 시장 : 유형별

• 개요
• 진단약
• 치료

제5장 급성 허혈성 뇌졸중 진단과 치료 시장 : 최종사용자별

• 개요
• 병원 및 진료소
• 외래 수술 센터
• 진단 연구소 및 영상 진단 센터
• 기타

제6장 급성 허혈성 뇌졸중 진단과 치료 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타
• 라틴아메리카·중동 및 아프리카
  • 브라질
  • 사우디아라비아
  • 남아프리카공화국
  • 기타

제7장 경쟁 구도

• 서론
• 주요 성공 전략
• 주요 10사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝, 2022년

제8장 기업 개요

• AstraZeneca plc
• F. Hoffmann-La Roche Ltd.
• GE Healthcare
• Boehringer Ingelheim International GmbH
• Koninklijke Philips N.V.
• Abbott Laboratories
• Siemens
• Medtronic plc
• Johnson & Johnson
• Stryker Corporation.

KSA

영문 목차

영문목차

According to a new report published by Allied Market Research, titled, "Acute Ischemic Stroke Diagnosis and Treatment Market," The acute ischemic stroke diagnosis and treatment market was valued at $5.1 billion in 2022, and is estimated to reach $9.2 billion by 2032, growing at a CAGR of 6.1% from 2023 to 2032. The Acute Ischemic Stroke Diagnosis and Treatment Market is likely to experience a significant growth rate of 6.1% from 2023-2032 owing to increase in demand for diagnostic technology from healthcare sector - Allied Market Research

Acute ischemic stroke (AIS) stands as the fourth leading cause of death and the primary cause of adult disability. This condition typically arises when a blood vessel obstruction occurs, resulting in irreversible brain injury and subsequent focal neurological deficits. The pharmacological approach to treating AIS revolves around intravenous thrombolysis using an alteplase, also known as recombinant tissue plasminogen activator (tPA). Alteplase administered intravenously facilitates thrombolysis by catalyzing the hydrolysis of plasminogen, forming the proteolytic enzyme plasmin.

The acute ischemic stroke diagnosis and treatment market has experienced significant growth owing to rise in prevalence of ischemic stroke. For instance, according to the World Stroke Organization Global Stroke Fact Sheet 2022, there were over 7.6 million new ischemic strokes each year and globally, over 62% of all incident strokes are ischemic strokes.

However, high cost of ischemic stroke diagnosis and treatment limits the market growth. For instance, according to World Stroke Organization (WSO), the Lancet Public Health article estimated treatment, rehabilitation, and indirect costs for stroke is more than $700 billion annually. Thus, high diagnosis and treatment cost negatively impact the market growth.

On the other hand, ongoing advancements in treatment options, including thrombolytic medications such as alteplase and innovative mechanical interventions like thrombectomy, drive the growth of the acute ischemic stroke market. These developments contribute to effective and timely management of acute ischemic strokes.

The acute ischemic stroke diagnosis and treatment market is segmented into type, end user, and region. By type, the market is segregated into diagnosis, and treatment. The diagnosis segment is further categorized into computed tomography, magnetic resonance imaging, carotid ultrasound, cerebral angiography, electrocardiography, echocardiography, and others. The treatment segment is bifurcated into thrombolytic therapy and mechanical thrombectomy. The thrombolytic therapy segment is further classified into tissue plasminogen activator, antiplatelet, and others. The mechanical thrombectomy segment is categorized into stent retriever and aspiration catheter, and combination (stent retriever and aspiration catheter). By end user, the market is divided into hospitals & clinics, diagnostic laboratories & diagnostic imaging centers, and others.

Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).

Major key players that operate in the acute ischemic stroke diagnosis and treatment market are AstraZeneca plc, F. Hoffmann-La Roche Ltd., Boehringer Ingelheim International GmbH, GE Healthcare, Koninklijke Philips N.V., Siemens, Abbott Laboratories Medtronic plc, Johnson & Johnson, and Stryker Corporation. Key players have adopted product approval, partnership, and agreement as key developmental strategies to improve the product portfolio of the acute ischemic stroke diagnosis and treatment market.

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the acute ischemic stroke diagnosis and treatment market analysis from 2022 to 2032 to identify the prevailing acute ischemic stroke diagnosis and treatment market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the acute ischemic stroke diagnosis and treatment market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global acute ischemic stroke diagnosis and treatment market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

• Diagnostics
  • Technology
  • Computed Tomography
  • Magnetic Resonance Imaging
  • Carotid Ultrasound
  • Cerebral Angiography
  • Electrocardiography
  • Echocardiography
  • Others
• Treatment
  • Type
  • Thrombolytic Therapy

Type

• Mechanical Thrombectomy

Type

By End User

• Hospitals and Clinics
• Ambulatory Surgery Centers
• Diagnostic Laboratories and Imaging Centers
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players:

• Boehringer Ingelheim International GmbH
• AstraZeneca plc
• Abbott Laboratories
• Stryker Corporation.
• Siemens
• Medtronic plc
• Johnson & Johnson
• F. Hoffmann-La Roche Ltd.
• Koninklijke Philips N.V.
• GE Healthcare

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
  • 3.3.1. Low bargaining power of suppliers
  • 3.3.2. Low threat of new entrants
  • 3.3.3. Low threat of substitutes
  • 3.3.4. Low intensity of rivalry
  • 3.3.5. Low bargaining power of buyers
• 3.4. Market dynamics
  • 3.4.1. Drivers
    • 3.4.1.1. Increase in incidence of stroke
    • 3.4.1.2. Advancements in imaging technologies
    • 3.4.1.3. Innovations in treatment option
  • 3.4.2. Restraints
    • 3.4.2.1. High cost of innovative therapies
  • 3.4.3. Opportunities
    • 3.4.3.1. High market growth potential in emerging markets

CHAPTER 4: ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Diagnostics
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
  • 4.2.4. Diagnostics Acute Ischemic Stroke Diagnosis and Treatment Market by Technology
• 4.3. Treatment
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
  • 4.3.4. Treatment Acute Ischemic Stroke Diagnosis and Treatment Market by Type
    • 4.3.4.1. Thrombolytic Therapy Acute Ischemic Stroke Diagnosis and Treatment Market by Type
    • 4.3.4.2. Mechanical Thrombectomy Acute Ischemic Stroke Diagnosis and Treatment Market by Type

CHAPTER 5: ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY END USER

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Hospitals and Clinics
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Ambulatory Surgery Centers
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Diagnostic Laboratories and Imaging Centers
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Others
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country

CHAPTER 6: ACUTE ISCHEMIC STROKE DIAGNOSIS AND TREATMENT MARKET, BY REGION

• 6.1. Overview
  • 6.1.1. Market size and forecast By Region
• 6.2. North America
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by Type
  • 6.2.3. Market size and forecast, by End User
  • 6.2.4. Market size and forecast, by country
    • 6.2.4.1. U.S.
    • 6.2.4.1.1. Market size and forecast, by Type
    • 6.2.4.1.2. Market size and forecast, by End User
    • 6.2.4.2. Canada
    • 6.2.4.2.1. Market size and forecast, by Type
    • 6.2.4.2.2. Market size and forecast, by End User
    • 6.2.4.3. Mexico
    • 6.2.4.3.1. Market size and forecast, by Type
    • 6.2.4.3.2. Market size and forecast, by End User
• 6.3. Europe
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by Type
  • 6.3.3. Market size and forecast, by End User
  • 6.3.4. Market size and forecast, by country
    • 6.3.4.1. Germany
    • 6.3.4.1.1. Market size and forecast, by Type
    • 6.3.4.1.2. Market size and forecast, by End User
    • 6.3.4.2. France
    • 6.3.4.2.1. Market size and forecast, by Type
    • 6.3.4.2.2. Market size and forecast, by End User
    • 6.3.4.3. UK
    • 6.3.4.3.1. Market size and forecast, by Type
    • 6.3.4.3.2. Market size and forecast, by End User
    • 6.3.4.4. Italy
    • 6.3.4.4.1. Market size and forecast, by Type
    • 6.3.4.4.2. Market size and forecast, by End User
    • 6.3.4.5. Spain
    • 6.3.4.5.1. Market size and forecast, by Type
    • 6.3.4.5.2. Market size and forecast, by End User
    • 6.3.4.6. Rest of Europe
    • 6.3.4.6.1. Market size and forecast, by Type
    • 6.3.4.6.2. Market size and forecast, by End User
• 6.4. Asia-Pacific
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by Type
  • 6.4.3. Market size and forecast, by End User
  • 6.4.4. Market size and forecast, by country
    • 6.4.4.1. Japan
    • 6.4.4.1.1. Market size and forecast, by Type
    • 6.4.4.1.2. Market size and forecast, by End User
    • 6.4.4.2. China
    • 6.4.4.2.1. Market size and forecast, by Type
    • 6.4.4.2.2. Market size and forecast, by End User
    • 6.4.4.3. India
    • 6.4.4.3.1. Market size and forecast, by Type
    • 6.4.4.3.2. Market size and forecast, by End User
    • 6.4.4.4. Australia
    • 6.4.4.4.1. Market size and forecast, by Type
    • 6.4.4.4.2. Market size and forecast, by End User
    • 6.4.4.5. South Korea
    • 6.4.4.5.1. Market size and forecast, by Type
    • 6.4.4.5.2. Market size and forecast, by End User
    • 6.4.4.6. Rest of Asia-Pacific
    • 6.4.4.6.1. Market size and forecast, by Type
    • 6.4.4.6.2. Market size and forecast, by End User
• 6.5. LAMEA
  • 6.5.1. Key market trends, growth factors and opportunities
  • 6.5.2. Market size and forecast, by Type
  • 6.5.3. Market size and forecast, by End User
  • 6.5.4. Market size and forecast, by country
    • 6.5.4.1. Brazil
    • 6.5.4.1.1. Market size and forecast, by Type
    • 6.5.4.1.2. Market size and forecast, by End User
    • 6.5.4.2. Saudi Arabia
    • 6.5.4.2.1. Market size and forecast, by Type
    • 6.5.4.2.2. Market size and forecast, by End User
    • 6.5.4.3. South Africa
    • 6.5.4.3.1. Market size and forecast, by Type
    • 6.5.4.3.2. Market size and forecast, by End User
    • 6.5.4.4. Rest of LAMEA
    • 6.5.4.4.1. Market size and forecast, by Type
    • 6.5.4.4.2. Market size and forecast, by End User

CHAPTER 7: COMPETITIVE LANDSCAPE

• 7.1. Introduction
• 7.2. Top winning strategies
• 7.3. Product mapping of top 10 player
• 7.4. Competitive dashboard
• 7.5. Competitive heatmap
• 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

• 8.1. AstraZeneca plc
  • 8.1.1. Company overview
  • 8.1.2. Key executives
  • 8.1.3. Company snapshot
  • 8.1.4. Operating business segments
  • 8.1.5. Product portfolio
  • 8.1.6. Business performance
  • 8.1.7. Key strategic moves and developments
• 8.2. F. Hoffmann-La Roche Ltd.
  • 8.2.1. Company overview
  • 8.2.2. Key executives
  • 8.2.3. Company snapshot
  • 8.2.4. Operating business segments
  • 8.2.5. Product portfolio
  • 8.2.6. Business performance
• 8.3. GE Healthcare
  • 8.3.1. Company overview
  • 8.3.2. Key executives
  • 8.3.3. Company snapshot
  • 8.3.4. Operating business segments
  • 8.3.5. Product portfolio
  • 8.3.6. Business performance
• 8.4. Boehringer Ingelheim International GmbH
  • 8.4.1. Company overview
  • 8.4.2. Key executives
  • 8.4.3. Company snapshot
  • 8.4.4. Operating business segments
  • 8.4.5. Product portfolio
  • 8.4.6. Business performance
• 8.5. Koninklijke Philips N.V.
  • 8.5.1. Company overview
  • 8.5.2. Key executives
  • 8.5.3. Company snapshot
  • 8.5.4. Operating business segments
  • 8.5.5. Product portfolio
  • 8.5.6. Business performance
  • 8.5.7. Key strategic moves and developments
• 8.6. Abbott Laboratories
  • 8.6.1. Company overview
  • 8.6.2. Key executives
  • 8.6.3. Company snapshot
  • 8.6.4. Operating business segments
  • 8.6.5. Product portfolio
  • 8.6.6. Business performance
• 8.7. Siemens
  • 8.7.1. Company overview
  • 8.7.2. Key executives
  • 8.7.3. Company snapshot
  • 8.7.4. Operating business segments
  • 8.7.5. Product portfolio
  • 8.7.6. Business performance
  • 8.7.7. Key strategic moves and developments
• 8.8. Medtronic plc
  • 8.8.1. Company overview
  • 8.8.2. Key executives
  • 8.8.3. Company snapshot
  • 8.8.4. Operating business segments
  • 8.8.5. Product portfolio
  • 8.8.6. Business performance
• 8.9. Johnson & Johnson
  • 8.9.1. Company overview
  • 8.9.2. Key executives
  • 8.9.3. Company snapshot
  • 8.9.4. Operating business segments
  • 8.9.5. Product portfolio
  • 8.9.6. Business performance
• 8.10. Stryker Corporation.
  • 8.10.1. Company overview
  • 8.10.2. Key executives
  • 8.10.3. Company snapshot
  • 8.10.4. Operating business segments
  • 8.10.5. Product portfolio
  • 8.10.6. Business performance

관련자료